{
    "symbol": "CPRX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 14:34:06",
    "content": " We reported GAAP net income of $22.7 million for the third quarter of 2022 or $0.22 per basic share, and $0.20 per share \u00e2\u0080\u0093 per diluted share, which also reflects a $4.6 million charge in the third quarter related to the accounting treatment for the write-down of the Ruzurgi inventory, and the amortization expense related to the acquisition of certain assets from Jacobus Pharmaceutical Company. We reported GAAP third quarter 2022 net income of $22.7 million or $0.22 per basic and $0.20 per diluted share, a 120.2% increase year-over-year compared to the third quarter 2021 GAAP net income of $10.3 million or $0.10 per basic and diluted share. Non-GAAP net income for the third quarter of 2022 was $28.6 million or $0.28 per basic and $0.26 per diluted share, which excludes from GAAP net income of $22.7 million stock-based compensation expense of $2.1 million, depreciation of $35,000, amortization of $518,000 related toward Q3 \u00e2\u0080\u009822 license and asset acquisition from Jacobus Pharmaceuticals and an income tax provision of $3.3 million."
}